Vasantharajan Janakiraman

TL;DR: The R-spondin gene fusions, several new recurrent mutations in the Wnt pathway gene TCF7L2, chromatin-remodelling genes such as TET2 and TET3 and receptor tyrosine kinases including ERBB3 are identified and shown to be capable of potentiating Wnt signalling.

TL;DR: This study provides an overview of the mutational spectra across major human cancers and identifies several potential therapeutic targets.

TL;DR: Exome, transcriptome and copy-number alteration data are obtained from approximately 53 samples consisting of 36 primary human SCLC and normal tissue pairs and 17 matched SCLCs and lymphoblastoid cell lines to identify several potential targets for therapeutic intervention.

TL;DR: It is found that the ERBB3 mutants transformed colonic and breast epithelial cells in a ligand-independent manner, however, the mutant ER BB3 oncogenic activity was dependent on kinase-active ERBB2.

TL;DR: Gene expression analysis identified a five-gene set that enabled the molecular classification of chRCC, renal oncocytoma and pRCC and observed upregulation of the anti-apoptotic factor BIRC7 in MiTF-high RCC tumors, suggesting a potential therapeutic role for BIRC 7 inhibitors.